請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/41044
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 楊雅倩(Ya-Chien Yang) | |
dc.contributor.author | Chia-Yun Chang | en |
dc.contributor.author | 張嘉芸 | zh_TW |
dc.date.accessioned | 2021-06-14T17:13:36Z | - |
dc.date.available | 2008-08-08 | |
dc.date.copyright | 2008-08-08 | |
dc.date.issued | 2008 | |
dc.date.submitted | 2008-07-25 | |
dc.identifier.citation | 1. Fearon, E.R. and B. Vogelstein, A genetic model for colorectal tumorigenesis. Cell, 1990. 61(5): p. 759-67.
2. Hawkins, N.J., C. Bariol, and R.L. Ward, The serrated neoplasia pathway. Pathology, 2002. 34(6): p. 548-55. 3. Kinzler, K.W., M.C. Nilbert, L.K. Su, B. Vogelstein, T.M. Bryan, D.B. Levy, K.J. Smith, A.C. Preisinger, P. Hedge, D. McKechnie, and et al., Identification of FAP locus genes from chromosome 5q21. Science, 1991. 253(5020): p. 661-5. 4. Nishisho, I., Y. Nakamura, Y. Miyoshi, Y. Miki, H. Ando, A. Horii, K. Koyama, J. Utsunomiya, S. Baba, and P. Hedge, Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science, 1991. 253(5020): p. 665-9. 5. Su, L.K., B. Vogelstein, and K.W. Kinzler, Association of the APC tumor suppressor protein with catenins. Science, 1993. 262(5140): p. 1734-7. 6. Rubinfeld, B., B. Souza, I. Albert, O. Muller, S.H. Chamberlain, F.R. Masiarz, S. Munemitsu, and P. Polakis, Association of the APC gene product with beta-catenin. Science, 1993. 262(5140): p. 1731-4. 7. Behrens, J., B.A. Jerchow, M. Wurtele, J. Grimm, C. Asbrand, R. Wirtz, M. Kuhl, D. Wedlich, and W. Birchmeier, Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science, 1998. 280(5363): p. 596-9. 8. Miyaki, M., M. Konishi, R. Kikuchi-Yanoshita, M. Enomoto, T. Igari, K. Tanaka, M. Muraoka, H. Takahashi, Y. Amada, M. Fukayama, and et al., Characteristics of somatic mutation of the adenomatous polyposis coli gene in colorectal tumors. Cancer Res, 1994. 54(11): p. 3011-20. 9. De Filippo, C., C. Luceri, G. Caderni, M. Pacini, L. Messerini, A. Biggeri, E. Mini, F. Tonelli, F. Cianchi, and P. Dolara, Mutations of the APC gene in human sporadic colorectal cancers. Scand J Gastroenterol, 2002. 37(9): p. 1048-53. 10. Cottrell, S., D. Bicknell, L. Kaklamanis, and W.F. Bodmer, Molecular analysis of APC mutations in familial adenomatous polyposis and sporadic colon carcinomas. Lancet, 1992. 340(8820): p. 626-30. 11. Diergaarde, B., W.L. van Geloof, G.N. van Muijen, F.J. Kok, and E. Kampman, Dietary factors and the occurrence of truncating APC mutations in sporadic colon carcinomas: a Dutch population-based study. Carcinogenesis, 2003. 24(2): p. 283-90. 12. Powell, S.M., N. Zilz, Y. Beazer-Barclay, T.M. Bryan, S.R. Hamilton, S.N. Thibodeau, B. Vogelstein, and K.W. Kinzler, APC mutations occur early during colorectal tumorigenesis. Nature, 1992. 359(6392): p. 235-7. 13. Sparks, A.B., P.J. Morin, B. Vogelstein, and K.W. Kinzler, Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res, 1998. 58(6): p. 1130-4. 14. Sodhi, A., S. Montaner, H. Miyazaki, and J.S. Gutkind, MAPK and Akt act cooperatively but independently on hypoxia inducible factor-1alpha in rasV12 upregulation of VEGF. Biochem Biophys Res Commun, 2001. 287(1): p. 292-300. 15. Downward, J., Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer, 2003. 3(1): p. 11-22. 16. Thiagalingam, S., C. Lengauer, F.S. Leach, M. Schutte, S.A. Hahn, J. Overhauser, J.K. Willson, S. Markowitz, S.R. Hamilton, S.E. Kern, K.W. Kinzler, and B. Vogelstein, Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet, 1996. 13(3): p. 343-6. 17. Parsons, R., L.L. Myeroff, B. Liu, J.K. Willson, S.D. Markowitz, K.W. Kinzler, and B. Vogelstein, Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res, 1995. 55(23): p. 5548-50. 18. Souza, R.F., R. Appel, J. Yin, S. Wang, K.N. Smolinski, J.M. Abraham, T.T. Zou, Y.Q. Shi, J. Lei, J. Cottrell, K. Cymes, K. Biden, L. Simms, B. Leggett, P.M. Lynch, M. Frazier, S.M. Powell, N. Harpaz, H. Sugimura, J. Young, and S.J. Meltzer, Microsatellite instability in the insulin-like growth factor II receptor gene in gastrointestinal tumours. Nat Genet, 1996. 14(3): p. 255-7. 19. el-Deiry, W.S., J.W. Harper, P.M. O'Connor, V.E. Velculescu, C.E. Canman, J. Jackman, J.A. Pietenpol, M. Burrell, D.E. Hill, Y. Wang, and et al., WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res, 1994. 54(5): p. 1169-74. 20. Weller, M., J. Rieger, C. Grimmel, E.G. Van Meir, N. De Tribolet, S. Krajewski, J.C. Reed, A. von Deimling, and J. Dichgans, Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses. Int J Cancer, 1998. 79(6): p. 640-4. 21. Baker, S.J., E.R. Fearon, J.M. Nigro, S.R. Hamilton, A.C. Preisinger, J.M. Jessup, P. vanTuinen, D.H. Ledbetter, D.F. Barker, Y. Nakamura, R. White, and B. Vogelstein, Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science, 1989. 244(4901): p. 217-21. 22. Hamelin, R., P. Laurent-Puig, S. Olschwang, N. Jego, B. Asselain, Y. Remvikos, J. Girodet, R.J. Salmon, and G. Thomas, Association of p53 mutations with short survival in colorectal cancer. Gastroenterology, 1994. 106(1): p. 42-8. 23. Wittekind, C.S., L. H., TNM classification of malignant tumours. New York: Wiley-Liss, 2002. sixth ed. 24. Laird, P.W., Cancer epigenetics. Hum Mol Genet, 2005. 14 Spec No 1: p. R65-76. 25. Novina, C.D. and P.A. Sharp, The RNAi revolution. Nature, 2004. 430(6996): p. 161-4. 26. Plass, C., Cancer epigenomics. Hum Mol Genet, 2002. 11(20): p. 2479-88. 27. Antequera, F. and A. Bird, Number of CpG islands and genes in human and mouse. Proc Natl Acad Sci U S A, 1993. 90(24): p. 11995-9. 28. Chuang, L.S., H.I. Ian, T.W. Koh, H.H. Ng, G. Xu, and B.F. Li, Human DNA-(cytosine-5) methyltransferase-PCNA complex as a target for p21WAF1. Science, 1997. 277(5334): p. 1996-2000. 29. Rountree, M.R., K.E. Bachman, and S.B. Baylin, DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat Genet, 2000. 25(3): p. 269-77. 30. Berger, J. and A. Bird, Role of MBD2 in gene regulation and tumorigenesis. Biochem Soc Trans, 2005. 33(Pt 6): p. 1537-40. 31. Englander, E.W., A.P. Wolffe, and B.H. Howard, Nucleosome interactions with a human Alu element. Transcriptional repression and effects of template methylation. J Biol Chem, 1993. 268(26): p. 19565-73. 32. Eden, A., F. Gaudet, A. Waghmare, and R. Jaenisch, Chromosomal instability and tumors promoted by DNA hypomethylation. Science, 2003. 300(5618): p. 455. 33. Toyota, M., N. Ahuja, M. Ohe-Toyota, J.G. Herman, S.B. Baylin, and J.P. Issa, CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A, 1999. 96(15): p. 8681-6. 34. Toyota, M. and J.P. Issa, CpG island methylator phenotypes in aging and cancer. Semin Cancer Biol, 1999. 9(5): p. 349-57. 35. Lyko, F. and R. Brown, DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst, 2005. 97(20): p. 1498-506. 36. Momparler, R.L., Epigenetic therapy of cancer with 5-aza-2'-deoxycytidine (decitabine). Semin Oncol, 2005. 32(5): p. 443-51. 37. Villar-Garea, A., M.F. Fraga, J. Espada, and M. Esteller, Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res, 2003. 63(16): p. 4984-9. 38. Arce, C., B. Segura-Pacheco, E. Perez-Cardenas, L. Taja-Chayeb, M. Candelaria, and A. Duennas-Gonzalez, Hydralazine target: from blood vessels to the epigenome. J Transl Med, 2006. 4: p. 10. 39. Brueckner, B., R.G. Boy, P. Siedlecki, T. Musch, H.C. Kliem, P. Zielenkiewicz, S. Suhai, M. Wiessler, and F. Lyko, Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res, 2005. 65(14): p. 6305-11. 40. Robert, M.F., S. Morin, N. Beaulieu, F. Gauthier, I.C. Chute, A. Barsalou, and A.R. MacLeod, DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet, 2003. 33(1): p. 61-5. 41. Yoo, C.B. and P.A. Jones, Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov, 2006. 5(1): p. 37-50. 42. Kuo, K.C., R.A. McCune, C.W. Gehrke, R. Midgett, and M. Ehrlich, Quantitative reversed-phase high performance liquid chromatographic determination of major and modified deoxyribonucleosides in DNA. Nucleic Acids Res, 1980. 8(20): p. 4763-76. 43. Fraga, M.F., E. Uriol, L. Borja Diego, M. Berdasco, M. Esteller, M.J. Canal, and R. Rodriguez, High-performance capillary electrophoretic method for the quantification of 5-methyl 2'-deoxycytidine in genomic DNA: application to plant, animal and human cancer tissues. Electrophoresis, 2002. 23(11): p. 1677-81. 44. Esteller, M., Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet, 2007. 8(4): p. 286-98. 45. Frommer, M., L.E. McDonald, D.S. Millar, C.M. Collis, F. Watt, G.W. Grigg, P.L. Molloy, and C.L. Paul, A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A, 1992. 89(5): p. 1827-31. 46. Herman, J.G., J.R. Graff, S. Myohanen, B.D. Nelkin, and S.B. Baylin, Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A, 1996. 93(18): p. 9821-6. 47. Eads, C.A., K.D. Danenberg, K. Kawakami, L.B. Saltz, C. Blake, D. Shibata, P.V. Danenberg, and P.W. Laird, MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res, 2000. 28(8): p. E32. 48. Xiong, Z. and P.W. Laird, COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res, 1997. 25(12): p. 2532-4. 49. Colella, S., L. Shen, K.A. Baggerly, J.P. Issa, and R. Krahe, Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. Biotechniques, 2003. 35(1): p. 146-50. 50. Kawai, J., S. Hirotsune, K. Hirose, S. Fushiki, S. Watanabe, and Y. Hayashizaki, Methylation profiles of genomic DNA of mouse developmental brain detected by restriction landmark genomic scanning (RLGS) method. Nucleic Acids Res, 1993. 21(24): p. 5604-8. 51. Takamiya, T., S. Hosobuchi, K. Asai, E. Nakamura, K. Tomioka, M. Kawase, T. Kakutani, A.H. Paterson, Y. Murakami, and H. Okuizumi, Restriction landmark genome scanning method using isoschizomers (MspI/HpaII) for DNA methylation analysis. Electrophoresis, 2006. 27(14): p. 2846-56. 52. Gonzalgo, M.L., G. Liang, C.H. Spruck, 3rd, J.M. Zingg, W.M. Rideout, 3rd, and P.A. Jones, Identification and characterization of differentially methylated regions of genomic DNA by methylation-sensitive arbitrarily primed PCR. Cancer Res, 1997. 57(4): p. 594-9. 53. Toyota, M., C. Ho, N. Ahuja, K.W. Jair, Q. Li, M. Ohe-Toyota, S.B. Baylin, and J.P. Issa, Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res, 1999. 59(10): p. 2307-12. 54. Frigola, J., M. Ribas, R.A. Risques, and M.A. Peinado, Methylome profiling of cancer cells by amplification of inter-methylated sites (AIMS). Nucleic Acids Res, 2002. 30(7): p. e28. 55. Yan, P.S., C.M. Chen, H. Shi, F. Rahmatpanah, S.H. Wei, and T.H. Huang, Applications of CpG island microarrays for high-throughput analysis of DNA methylation. J Nutr, 2002. 132(8 Suppl): p. 2430S-2434S. 56. Suzuki, S.T., Recent progress in protocadherin research. Exp Cell Res, 2000. 261(1): p. 13-8. 57. Suzuki, S.T., Structural and functional diversity of cadherin superfamily: are new members of cadherin superfamily involved in signal transduction pathway? J Cell Biochem, 1996. 61(4): p. 531-42. 58. Yagi, T. and M. Takeichi, Cadherin superfamily genes: functions, genomic organization, and neurologic diversity. Genes Dev, 2000. 14(10): p. 1169-80. 59. Nollet, F., P. Kools, and F. van Roy, Phylogenetic analysis of the cadherin superfamily allows identification of six major subfamilies besides several solitary members. J Mol Biol, 2000. 299(3): p. 551-72. 60. Hirano, S., S.T. Suzuki, and C. Redies, The cadherin superfamily in neural development: diversity, function and interaction with other molecules. Front Biosci, 2003. 8: p. d306-55. 61. Redies, C., K. Vanhalst, and F. Roy, delta-Protocadherins: unique structures and functions. Cell Mol Life Sci, 2005. 62(23): p. 2840-52. 62. Frank, M. and R. Kemler, Protocadherins. Curr Opin Cell Biol, 2002. 14(5): p. 557-62. 63. Takeichi, M., Cadherins: a molecular family important in selective cell-cell adhesion. Annu Rev Biochem, 1990. 59: p. 237-52. 64. Sano, K., H. Tanihara, R.L. Heimark, S. Obata, M. Davidson, T. St John, S. Taketani, and S. Suzuki, Protocadherins: a large family of cadherin-related molecules in central nervous system. Embo J, 1993. 12(6): p. 2249-56. 65. Miller, J.R. and D.R. McClay, Characterization of the role of cadherin in regulating cell adhesion during sea urchin development. Dev Biol, 1997. 192(2): p. 323-39. 66. Levi, L., J. Douek, M. Osman, T.C. Bosch, and B. Rinkevich, Cloning and characterization of BS-cadherin, a novel cadherin from the colonial urochordate Botryllus schlosseri. Gene, 1997. 200(1-2): p. 117-23. 67. Uemura, T., H. Oda, R. Kraut, S. Hayashi, Y. Kotaoka, and M. Takeichi, Zygotic Drosophila E-cadherin expression is required for processes of dynamic epithelial cell rearrangement in the Drosophila embryo. Genes Dev, 1996. 10(6): p. 659-71. 68. Bradley, R.S., A. Espeseth, and C. Kintner, NF-protocadherin, a novel member of the cadherin superfamily, is required for Xenopus ectodermal differentiation. Curr Biol, 1998. 8(6): p. 325-34. 69. Suzuki, S.T., Protocadherins and diversity of the cadherin superfamily. J Cell Sci, 1996. 109 ( Pt 11): p. 2609-11. 70. Wu, Q. and T. Maniatis, A striking organization of a large family of human neural cadherin-like cell adhesion genes. Cell, 1999. 97(6): p. 779-90. 71. Wolverton, T. and M. Lalande, Identification and characterization of three members of a novel subclass of protocadherins. Genomics, 2001. 76(1-3): p. 66-72. 72. Vanhalst, K., P. Kools, K. Staes, F. van Roy, and C. Redies, delta-Protocadherins: a gene family expressed differentially in the mouse brain. Cell Mol Life Sci, 2005. 62(11): p. 1247-59. 73. Hirano, S., Q. Yan, and S.T. Suzuki, Expression of a novel protocadherin, OL-protocadherin, in a subset of functional systems of the developing mouse brain. J Neurosci, 1999. 19(3): p. 995-1005. 74. Nagase, T., R. Kikuno, K.I. Ishikawa, M. Hirosawa, and O. Ohara, Prediction of the coding sequences of unidentified human genes. XVI. The complete sequences of 150 new cDNA clones from brain which code for large proteins in vitro. DNA Res, 2000. 7(1): p. 65-73. 75. Muller, K., S. Hirano, L. Puelles, and C. Redies, OL-protocadherin expression in the visual system of the chicken embryo. J Comp Neurol, 2004. 470(3): p. 240-55. 76. Luckner, R., K. Obst-Pernberg, S. Hirano, S.T. Suzuki, and C. Redies, Granule cell raphes in the developing mouse cerebellum. Cell Tissue Res, 2001. 303(2): p. 159-72. 77. Nakao, S., M. Uemura, E. Aoki, S.T. Suzuki, M. Takeichi, and S. Hirano, Distribution of OL-protocadherin in axon fibers in the developing chick nervous system. Brain Res Mol Brain Res, 2005. 134(2): p. 294-308. 78. Berx, G., A.M. Cleton-Jansen, F. Nollet, W.J. de Leeuw, M. van de Vijver, C. Cornelisse, and F. van Roy, E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. Embo J, 1995. 14(24): p. 6107-15. 79. Perl, A.K., P. Wilgenbus, U. Dahl, H. Semb, and G. Christofori, A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature, 1998. 392(6672): p. 190-3. 80. Graff, J.R., J.G. Herman, R.G. Lapidus, H. Chopra, R. Xu, D.F. Jarrard, W.B. Isaacs, P.M. Pitha, N.E. Davidson, and S.B. Baylin, E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res, 1995. 55(22): p. 5195-9. 81. Yoshiura, K., Y. Kanai, A. Ochiai, Y. Shimoyama, T. Sugimura, and S. Hirohashi, Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci U S A, 1995. 92(16): p. 7416-9. 82. Toyooka, K.O., S. Toyooka, A.K. Virmani, U.G. Sathyanarayana, D.M. Euhus, M. Gilcrease, J.D. Minna, and A.F. Gazdar, Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res, 2001. 61(11): p. 4556-60. 83. Miotto, E., S. Sabbioni, A. Veronese, G.A. Calin, S. Gullini, A. Liboni, L. Gramantieri, L. Bolondi, E. Ferrazzi, R. Gafa, G. Lanza, and M. Negrini, Frequent aberrant methylation of the CDH4 gene promoter in human colorectal and gastric cancer. Cancer Res, 2004. 64(22): p. 8156-9. 84. Mahoney, P.A., U. Weber, P. Onofrechuk, H. Biessmann, P.J. Bryant, and C.S. Goodman, The fat tumor suppressor gene in Drosophila encodes a novel member of the cadherin gene superfamily. Cell, 1991. 67(5): p. 853-68. 85. Dunne, J., A.M. Hanby, R. Poulsom, T.A. Jones, D. Sheer, W.G. Chin, S.M. Da, Q. Zhao, P.C. Beverley, and M.J. Owen, Molecular cloning and tissue expression of FAT, the human homologue of the Drosophila fat gene that is located on chromosome 4q34-q35 and encodes a putative adhesion molecule. Genomics, 1995. 30(2): p. 207-23. 86. Paz, M.F., S. Wei, J.C. Cigudosa, S. Rodriguez-Perales, M.A. Peinado, T.H. Huang, and M. Esteller, Genetic unmasking of epigenetically silenced tumor suppressor genes in colon cancer cells deficient in DNA methyltransferases. Hum Mol Genet, 2003. 12(17): p. 2209-19. 87. Okazaki, N., N. Takahashi, S. Kojima, Y. Masuho, and H. Koga, Protocadherin LKC, a new candidate for a tumor suppressor of colon and liver cancers, its association with contact inhibition of cell proliferation. Carcinogenesis, 2002. 23(7): p. 1139-48. 88. Ying, J., H. Li, T.J. Seng, C. Langford, G. Srivastava, S.W. Tsao, T. Putti, P. Murray, A.T. Chan, and Q. Tao, Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene, 2006. 25(7): p. 1070-80. 89. Ying, J., Z. Gao, H. Li, G. Srivastava, P.G. Murray, H.K. Goh, C.Y. Lim, Y. Wang, T. Marafioti, D.Y. Mason, R.F. Ambinder, A.T. Chan, and Q. Tao, Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies. Br J Haematol, 2007. 136(6): p. 829-32. 90. Yu, L., C. Liu, J. Vandeusen, B. Becknell, Z. Dai, Y.Z. Wu, A. Raval, T.H. Liu, W. Ding, C. Mao, S. Liu, L.T. Smith, S. Lee, L. Rassenti, G. Marcucci, J. Byrd, M.A. Caligiuri, and C. Plass, Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. Nat Genet, 2005. 37(3): p. 265-74. 91. Esteller, M., Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet, 2007. 16 Spec No 1: p. R50-9. 92. Katzenellenbogen, R.A., S.B. Baylin, and J.G. Herman, Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood, 1999. 93(12): p. 4347-53. 93. Kang, G.H., Y.H. Shim, H.Y. Jung, W.H. Kim, J.Y. Ro, and M.G. Rhyu, CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res, 2001. 61(7): p. 2847-51. 94. Dong, S.M., H.S. Kim, S.H. Rha, and D. Sidransky, Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin Cancer Res, 2001. 7(7): p. 1982-6. 95. Chan, M.W., L.W. Chan, N.L. Tang, J.H. Tong, K.W. Lo, T.L. Lee, H.Y. Cheung, W.S. Wong, P.S. Chan, F.M. Lai, and K.F. To, Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res, 2002. 8(2): p. 464-70. 96. Kim, D.H., H.H. Nelson, J.K. Wiencke, D.C. Christiani, J.C. Wain, E.J. Mark, and K.T. Kelsey, Promoter methylation of DAP-kinase: association with advanced stage in non-small cell lung cancer. Oncogene, 2001. 20(14): p. 1765-70. 97. Kwong, J., K.W. Lo, K.F. To, P.M. Teo, P.J. Johnson, and D.P. Huang, Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin Cancer Res, 2002. 8(1): p. 131-7. 98. Satoh, A., M. Toyota, F. Itoh, T. Kikuchi, T. Obata, Y. Sasaki, H. Suzuki, A. Yawata, M. Kusano, M. Fujita, M. Hosokawa, K. Yanagihara, T. Tokino, and K. Imai, DNA methylation and histone deacetylation associated with silencing DAP kinase gene expression in colorectal and gastric cancers. Br J Cancer, 2002. 86(11): p. 1817-23. 99. Yamaguchi, S., T. Asao, J. Nakamura, M. Ide, and H. Kuwano, High frequency of DAP-kinase gene promoter methylation in colorectal cancer specimens and its identification in serum. Cancer Lett, 2003. 194(1): p. 99-105. 100. Herman, J.G., A. Umar, K. Polyak, J.R. Graff, N. Ahuja, J.P. Issa, S. Markowitz, J.K. Willson, S.R. Hamilton, K.W. Kinzler, M.F. Kane, R.D. Kolodner, B. Vogelstein, T.A. Kunkel, and S.B. Baylin, Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A, 1998. 95(12): p. 6870-5. 101. Morishita, H., M. Umitsu, Y. Murata, N. Shibata, K. Udaka, Y. Higuchi, H. Akutsu, T. Yamaguchi, T. Yagi, and T. Ikegami, Structure of the cadherin-related neuronal receptor/protocadherin-alpha first extracellular cadherin domain reveals diversity across cadherin families. J Biol Chem, 2006. 281(44): p. 33650-63. 102. Morishita, H. and T. Yagi, Protocadherin family: diversity, structure, and function. Curr Opin Cell Biol, 2007. 19(5): p. 584-92. 103. Hirsch, J. and E. Schlatter, Genistein potentiates the ANP effect on a K(+)-conductance in HEK-293 cells. Cell Physiol Biochem, 2003. 13(4): p. 223-8. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/41044 | - |
dc.description.abstract | 大腸直腸癌 (colorectal cancer, CRC)是常見的癌症,為國人癌症十大死因的第三名,偶發性CRC發生過程大多會從腺瘤變成腺癌,且又依照不同的基因轉變分為LOH (loss of heterozygosity)及MSI (microsatellite instability)兩種路徑。除了基因序列變異的累積會造成癌細胞的發展,基因後生遺傳修飾 (epigenetic modification)也扮演重要角色。常見的基因後生遺傳修飾調控即藉由DNA methyltransferases (DNMTs)將基因啟動子 (promoter) CpG位點之cytosine第5號碳進行甲基化 (mC)。CpG甲基化會抑制啟動子和轉錄因子 (transcription factors, TFs)的結合,使基因無法轉錄。目前CRC後生遺傳修飾的研究上,已發現許多抑癌基因受到DNA甲基化抑制的調控。本研究室於尋找CRC相關抑癌基因的研究中,分析腫瘤在第四號染色體微衛星標記發生LOH的情形,結果於4q25-4q28.3發現三個LOH發生率高的區域,而細胞吸附分子protocadherin 10 (PCDH10)基因即位於其中一個區域上。近期有研究指出PCDH10可能是抑癌基因,在鼻咽癌、血癌或其他腫瘤中,此基因的表現似乎受到後生遺傳修飾的抑制。為了探討大腸直腸癌中PCDH10基因是否受到啟動子過度甲基化 (promoter hypermethylation)的調控,本論文利用一系列DNA甲基化分析方法,檢測大腸直腸癌細胞株及CRC病人檢體PCDH10甲基化情形,並進一步統計PCDH10甲基化與臨床資料及其他癌症相關基因甲基化的相關性。結果顯示,CRC腫瘤之PCDH10甲基化程度明顯高於大腸正常黏膜組織,並具有統計上顯著差異,而腫瘤之PCDH10甲基化於病患年齡、性別、腫瘤位置、腫瘤分化程度及CRC分期則無顯著差異。此外,藉由DNA去甲基化藥物5-aza-2'-deoxycytidine (5-Aza-CdR)處理CRC細胞株SW620,可使PCDH10基因啟動子去甲基化並恢復其mRNA的表現,進一步證明在大腸直腸癌中,PCDH10基因的表現確實受到DNA甲基化的調控。 | zh_TW |
dc.description.abstract | Colorectal cancer (CRC) is one of the most common malignancies and is the third leading cause of cancer death in Taiwan. Most sporadic CRCs are thought to develop from benign adenomas to carcinoma. The two major pathways in colorectal carcinogenesis, LOH (loss of heterozygosity) and MSI (microsatellite instability), accumulate different genetic abnormalities. Tumorigenesis is not only linked to genetic alteration as a contribution but also to epigenetic regulation as a major player in cancer development. DNA methylation remains the best-studied epigenetic mechanism. Methylation at the C-5 position of cytosine residues present in CpG dinucleotides by DNA methyltransferases (DNMTs). This methylation inhibits gene expression by directly blocking the binding of transcription factors (TFs) to the target gene promoter sequence. Tumor suppressor genes (TSGs) silencing by DNA methylation has been found in many cases of cancer. In our preliminary study of LOH frequency on chromosome 4 in cases of CRC, three LOH loci were frequently defined around 4q25-4q28.3. A cell adhesion molecule, protocadherin 10 (PCDH10), is located in one of these regions. In a recent study, PCDH10 was identified as a candidate TSG due to frequent silencing in nasopharyngeal, esophageal, lymphoma and multiple other carcinomas by DNA methylation. However, there is little known about PCDH10 methylation in CRC. Therefore, the purpose of this study was to deremine whether PCDH10 expression is regulated by DNA methylation. We analyzed the frequency of PCDH10 methylation in CRC cell lines and patient tissue samples. Our studies revealed that PCDH10 was highly methylated in both CRC cell lines and CRC tissues. Methylation of PCDH10 between tumor tissues of CRC patients and adjacent normal mucosa was significant, but was not necessarily correlated to age, sex, tumor location, tumor differentiation, or Dukes' stage. On the other hand, the colon cancer cell, SW620, once treated with an epigenetic demethylation drug, 5-aza-2'-deoxycytidine (5-Aza-CdR), can restore PCDH10 RNA expression. Thus, PCDH10 expression is regulated by epigenetic modification and is frequently methylated in CRC. | en |
dc.description.provenance | Made available in DSpace on 2021-06-14T17:13:36Z (GMT). No. of bitstreams: 1 ntu-97-R95424003-1.pdf: 2940816 bytes, checksum: 82a3302d4f2d65262ad48f75f190b12f (MD5) Previous issue date: 2008 | en |
dc.description.tableofcontents | 致謝 i
中文摘要 ii 英文摘要 iii 第一章 緒論 1 第一節 大腸直腸癌簡介 1 1. 大腸直腸癌 1 2. 大腸直腸癌的分期 3 第二節 基因後生遺傳修飾作用 5 1. 基因後生遺傳調控 5 2. 基因後生遺傳修飾藥物 7 3. 研究基因後生遺傳修飾的方法 8 第三節 Protocadherin 10 10 1. Cadherin superfamily 10 2. Protocadherin 10 3. PCDH10 11 第四節 研究目的 12 第二章 材料與方法 13 第一節 實驗材料 13 1. 細胞株 13 2. 細胞株培養 13 3. 大腸直腸組織 13 4. 健康者周邊血液 14 第二節 實驗方法 14 1. 抽取細胞株DNA 14 2. 抽取組織DNA 14 3. 抽取周邊血液DNA 15 4. 抽取細胞株RNA 15 5. 反轉錄-聚合酶連鎖反應 16 6. DNA及RNA濃度測量 16 7. DNA亞硫酸鈉處理 16 8. 甲基化特異性聚合酶連鎖反應 17 9. 亞硫酸鹽定序聚合酶連鎖反應 17 10. 結合亞硫酸鹽處理及限制酶分析法 18 11. DAPK1、hMLH1 及 PCDH10 基因甲基化之定義 19 12. 細胞增生及活性測試 19 13. 測試5-Aza-CdR處理對SW620之PCDH10基因去甲基化及RNA表現的影響 21 第三節 統計分析 21 第三章 實驗結果 22 第一節 DAPK1基因甲基化分析之結果 22 第二節 hMLH1 基因甲基化分析之結果 22 第三節 PCDH10 基因甲基化分析之結果 23 第四節 大腸直腸癌檢體基因甲基化與臨床資料的統計分析 25 第五節 大腸直腸癌細胞PCDH10基因mRNA的表現 29 第六節 以DNA去甲基化藥物處理大腸直腸癌細胞後對PCDH10基因表現的影響 30 第四章 討論 32 圖 36 表 61 參考文獻 73 附圖 80 附表 82 圖目錄 Figure 1. Methylation status of Death-associated protein kinase 1 (DAPK1) CpG island in cell lines and colorectal cancer (CRC) tissues 36 Figure 2. Methylation status of human mutL homolog 1 (hMLH1) CpG island in cell lines and colorectal cancer (CRC) tissues 37 Figure 3. Methylation status of Protocadherin10 (PCDH10) CpG island in cell lines, peripheral blood mononuclear cells (PBMCs) and colorectal tissues 38 Figure 4. Combined bisulfite restriction analysis of Protocadherin10 (PCDH10) CpG island in cell lines, peripheral blood mononuclear cells (PBMC) and CRC tissues 40 Figure 5. Bisulfite sequence analysis of Protocadherin10 (PCDH10) promoter CpG island in cell lines, peripheral blood mononuclear cells (PBMC) and colorectal tissues. 41 Figure 6. Promoter methylation and RNA expression of Protocadherin10 (PCDH10) in cell lines, peripheral blood mononuclear cells (PBMCs) and colorectal tissues 44 Figure 7. Methylation frequency of Protocadherin10 (PCDH10) at each CpG site in 12 CRC cell lines, 2 peripheral blood mononuclear cells (PBMCs) and 7 pairs of CRC tissues 45 Figure 8. Clinicopathological correlation of DAPK1、hMLH1 and PCDH10 gene methylation with age in CRC by regression analysis 46 Figure 9. Clinicopathological correlation of DAPK1、hMLH1 and PCDH10 gene methylation with age in CRC by unpair t-test 47 Figure 10. Clinicopathological correlation of hMLH1 and PCDH10 gene methylation between normal mucosa and tumors in CRC 48 Figure 11. Clinicopathological correlation of hMLH1 and PCDH10 gene methylation with gender in CRC 49 Figure 12. Clinicopathological correlation of hMLH1 and PCDH10 gene methylation with tumor location in CRC 50 Figure 13. Clinicopathological correlation of hMLH1 and PCDH10 gene methylation with tumor differentiation in CRC 51 Figure 14. Clinicopathological correlation of hMLH1 and PCDH10 gene methylation with Dukes' stage in CRC 52 Figure 15. Clinicopathological correlation of hMLH1 and PCDH10 gene methylation with disease-free survival in CRC tumors 53 Figure 16. Clinicopathological correlation of hMLH1 and PCDH10 methylation with overall survival in CRC tumors 54 Figure 17. PCDH10 mRNA expression in cell lines and CRC normal mucosa 55 Figure 18. Cell proliferation assay of SW480 and SW620 56 Figure 19. Cytotoxicity assay of 5-aza-2’-deoxycytidine (5-Aza-CdR) on SW480 and SW620 57 Figure 20. DNA demethylation and restored mRNA expression of Protocadherin10 (PCDH10) by 5-aza-2’-deoxycytidine (5-Aza-CdR) treatment 58 表目錄 Table 1. Cell line culture condition 61 Table 2. PCR primers used 63 Table 3. PCDH10 RT-PCR condition 64 Table 4. GAPDH RT-PCR condition 65 Table 5. DAPK1 MSP condition 66 Table 6. hMLH1 MSP condition 67 Table 7. PCDH10 MSP condition 68 Table 8. PCDH10 BSP condition 69 Table 9. PCDH10 COBRA condition 70 Table 10. Clinicopathological charateristics of CRC patients 71 Table 11. Clinicopathological correlation of DAPK1、hMLH1 and PCDH10 methylation in CRC 72 | |
dc.language.iso | zh-TW | |
dc.title | 大腸直腸癌之PCDH10基因後生遺傳的研究 | zh_TW |
dc.title | Epigenetic Study of PCDH10 Gene in Colorectal Cancer | en |
dc.type | Thesis | |
dc.date.schoolyear | 96-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 林亮音(Liang-In Lin),俞松良(Sung-Liang Yu),蔡明宏(Tsai-Ming Hung) | |
dc.subject.keyword | 大腸直腸癌,PCDH10,後生遺傳修飾,DNA甲基化, | zh_TW |
dc.subject.keyword | Colorectal cancer,PCDH10,Epigenetic modification,DNA methylation, | en |
dc.relation.page | 82 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2008-07-28 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 醫學檢驗暨生物技術學研究所 | zh_TW |
顯示於系所單位: | 醫學檢驗暨生物技術學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-97-1.pdf 目前未授權公開取用 | 2.87 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。